By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

FibroGen, Inc. has announced the sale of its Chinese subsidiary to AstraZeneca, including the rights to roxadustat in China.

A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

Researchers at Penn Medicine conducted a pilot randomized controlled trial to test the hypothesis that an e-triage ...

BEIJING (Kyodo) -- Chinese Commerce Minister Wang Wentao on Tuesday urged Japanese business leaders to "join hands" with ...

What is a menopause health assessment? And how will it improve the health care women receive during this stage in their lives ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...